Interview: Oryzon Chief Highlights CNS Opportunities

After the setback of Roche pulling the plug on a potentially lucrative cancer partnership last year, the Spanish biotech tells Scrip it has bounced back with a compound that shows potential in Alzheimer's, multiple sclerosis and other neurodegenerative and psychiatric diseases.